Petrelintide
Also known as ZP8396
Petrelintide is an experimental weekly amylin-mimicking injection being tested for weight loss on its own — the idea is Ozempic-style appetite control with a gentler side-effect profile.
How one dose clears
modeled over ~6 half-lives- Half-life
- 10.0 days
- Time to peak (Tmax)
- 3.0 days
- Bioavailability
- 85%
- Steady state
- ~49 days
- Typical dose
- 1.2 mg
Investigational long-acting amylin analog for obesity, designed for once-weekly subcutaneous dosing (often studied alongside GLP-1 agonists).
Mechanism of action
Amylin-receptor agonism promotes satiety and slows gastric emptying, complementing GLP-1 pathways.
Investigational — not approved. Terminal half-life ~10 days (once-weekly dosing); ~85% bioavailability.
References
Track Petrelintide for free
Log your doses and PeptideBuddy models Petrelintide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking freeFree. No card required.